c-Maf CRISPR/Cas9 KO Plasmid (h2): sc-410543-KO-2
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- c-Maf CRISPR/Cas9 Knockout (KO) Plasmid (h2) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the c-Maf genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: c-Maf Antibody (6B8): sc-293420
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
c-Maf CRISPR/Cas9 KO Plasmid (h2) | sc-410543-KO-2 | 20 µg | $397.00 |
Overview
MAF encodes c-Maf, a basic leucine zipper (bZIP) transcription factor that binds Maf recognition elements to regulate context-dependent gene expression programs. In human cells, c-Maf integrates differentiation and stress-responsive signaling, influencing lineage specification, cytokine and extracellular matrix gene transcription, and coordination of cell-cycle and survival pathways. c-Maf activity intersects with immune signaling networks and developmental transcriptional circuits, shaping macrophage and T-cell functional states as well as tissue homeostasis. Dysregulated MAF expression or altered c-Maf transcriptional output is associated with aberrant differentiation and proliferative phenotypes observed across multiple disease-relevant research contexts, including hematologic malignancy models and inflammatory biology.
c-Maf CRISPR/Cas9 KO Plasmid (h2) is a pool of plasmids designed for targeted disruption of the MAF gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the MAF together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the MAF open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish c-Maf protein expression.
This CRISPR knockout system enables efficient generation of MAF-deficient cell models for investigation of c-Maf signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting MAF exon(s) critical for c-Maf function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple MAF genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by c-Maf CRISPR/Cas9 KO Plasmid (h) and c-Maf CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the MAF locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by c-Maf HDR Plasmid (h) and c-Maf HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by MAF homology arms to support homology-directed repair at defined MAF target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.